Fox Run Management L.L.C. Purchases New Stake in Fresenius Medical Care AG (NYSE:FMS)

Fox Run Management L.L.C. purchased a new position in Fresenius Medical Care AG (NYSE:FMS) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 18,195 shares of the company’s stock, valued at approximately $412,000.

Other hedge funds have also recently modified their holdings of the company. Smartleaf Asset Management LLC increased its holdings in Fresenius Medical Care by 192.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock valued at $28,000 after purchasing an additional 806 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Fresenius Medical Care during the third quarter valued at approximately $38,000. Jones Financial Companies Lllp raised its holdings in shares of Fresenius Medical Care by 80.5% during the fourth quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company’s stock valued at $102,000 after acquiring an additional 2,012 shares in the last quarter. Venturi Wealth Management LLC lifted its stake in Fresenius Medical Care by 8.4% in the fourth quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company’s stock worth $129,000 after acquiring an additional 441 shares during the period. Finally, GAMMA Investing LLC increased its position in Fresenius Medical Care by 43.3% during the 4th quarter. GAMMA Investing LLC now owns 7,164 shares of the company’s stock valued at $162,000 after purchasing an additional 2,166 shares during the period. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Bank of America raised shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. StockNews.com upgraded Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Finally, Truist Financial lifted their price target on Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research report on Monday, January 6th.

Fresenius Medical Care Trading Up 0.6 %

Shares of NYSE FMS opened at $24.45 on Wednesday. Fresenius Medical Care AG has a 1 year low of $17.93 and a 1 year high of $25.25. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The firm has a 50-day moving average of $23.93 and a 200 day moving average of $22.45. The stock has a market cap of $14.35 billion, a P/E ratio of 20.21, a price-to-earnings-growth ratio of 0.76 and a beta of 0.99.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.